ReviewCureus2026
Gastrointestinal Involvement in Adult IgA Vasculitis: A Comprehensive Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin A vasculitis (IgAV), formerly Henoch-Schönlein purpura (HSP), is a small-vessel vasculitis with IgA (immunoglobulin A) immune complex deposition that predominantly affects the skin, joints, kidneys, and gastrointestinal (GI) tract. While less common in adults than in children, IgAV (immunoglobulin A vasculitis) is more severe and less well-characterized in adults. GI involvement in adults is associated with significant morbidity, motivating a comprehensive understanding of IgAV pathophysiology, diagnosis, and management. We synthesized current literature on adult IgAV with GI involvement, including its epidemiology, immune mechanisms, genetic drivers, diagnostic approaches, treatment modalities, and prognostic factors. The pathogenesis of IgA vasculitis involves immune complex-mediated small-vessel inflammation driven by aberrant IgA responses, proinflammatory cytokines, genetic predisposition, and environmental triggers. GI involvement occurs in 37-65% of adult IgAV cases, with symptoms ranging from abdominal pain and hematochezia to severe complications such as perforation and ischemia. Diagnosis relies on measurement of laboratory markers (elevated C-reactive protein, Neutrophil-to-Lymphocyte ratio, D-dimer) and imaging (computed tomography, endoscopy). Treatment includes corticosteroids for moderate-to-severe cases, with immunosuppressants (mycophenolate mofetil, intravenous immunoglobulins) reserved for refractory cases. Surgical intervention is rare but necessary in cases of life-threatening complications. Prognostic factors include age, renal involvement, and genetic markers. Adult GI IgAV requires early recognition and a multidisciplinary approach for effective management. Future research should explore advanced biomarkers and therapeutic strategies to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.